Efficacy, safety and mechanism of metformin in the treatment of colorectal polyps

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062649

Enrollment

Unknown

Registered

2022-08-14

Start date

2022-08-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal polyps

Interventions

The control group:All polyps of large intestine were removed by colonoscopy

500 mg/day group:After colonoscopic resection of all polyps, oral metformin 500mg/ day was started

1000 mg/day group:After colonoscopic resection of all polyps, oral metformin 1000mg/ day was started

1500 mg/day group:After colonoscopic resection of all polyps, oral metformin 1500mg/ day was started

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. No residual polyp existed after colorectal polypectomy; 2. Aged 18 - 65 years; 3. Willing to sign the informed consent for enrollment.

Exclusion criteria

Exclusion criteria: 1. History of diabetes; 2. Have a history of metformin allergy or cannot tolerate its side effects; 3. Non-steroidal anti-inflammatory drugs, berberine hydrochloride, curcumin, aspirin, calcium supplements, vitamin D, green tea or polyphenol E supplements have been used in the last six months (if any, the drug use history should be included during the six-month washout period), and the drug use during the study will also be excluded; 4. History of colorectal surgery; 5. Have a history of malignant tumor (excluding radical endoscopic resection of the lesion); 6. Suffering from heart failure, liver failure, kidney failure and liver cirrhosis and other serious diseases; 7. Suffering from familial adenomatous polyposis; 8. A history of inflammatory bowel disease; 9. Patients considered unsuitable for participation by the researchers.

Design outcomes

Primary

Measure	Time frame
Changes in size, number and location of colonic polyps;Adverse reactions;Wnt/ß-catenin/APC gene expression;	—

Secondary

Measure	Time frame
Hemoglobin a1c;fasting insulin test;fasting blood glucose;folic acid;homocysteine;serum ferritin;vitamin B12;blood routine;biochemical complete set;ESR;	—

Countries

China

Contacts

Public ContactSun Dongjie

900th Hospital of Joint Logistics Support Force, PLA

282220278@qq.com+86 17085938120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026